Literature DB >> 28417868

Risk Factors for Unanticipated Readmissions During the Interstage: A Report From the National Pediatric Cardiology Quality Improvement Collaborative.

Samuel P Hanke1, Brian Joy2, Elise Riddle3, Chitra Ravishankar4, Laura E Peterson5, Eileen King6, Colleen Mangeot6, David W Brown7, Pamela Schoettker6, Jeffrey B Anderson6, Katherine E Bates8.   

Abstract

This study describes unanticipated interstage readmissions in patients with hypoplastic left heart syndrome, identifies independent risk factors for unanticipated interstage readmissions, and evaluates variation in unanticipated readmission rates among collaborative centers. Retrospective data of patients enrolled in the National Pediatric Cardiology Quality Improvement Collaborative registry from July 2008 to July 2013 were analyzed. Risk factors present at the beginning of the interstage were captured. Competing risks time to event analyses determined the association between these factors and unanticipated interstage readmission. Readmission center variation was examined using funnel plots. Unanticipated interstage readmissions occurred in 66% of 815 patients at 50 centers. The median readmission length of stay was 2 days (interquartile range: 0-6) and median time to first readmission was 29 days (interquartile range: 9-63). Most readmissions were prompted by minor changes in clinical status (64%), whereas only 6% were major adverse event readmissions. Independent readmission risk factors included genetic syndrome (HR = 1.40, 95% CI: 1.05-1.88), center volume (small vs large HR = 1.32, CI: 1.04-1.66, medium vs large HR = 1.35, CI: 1.09-1.68), preoperative ventricular dysfunction (HR = 2.02, CI: 1.31-3.10), tricuspid regurgitation (HR = 1.36, CI: 1.08-1.72), duration of circulatory arrest (HR = 0.99, CI: 0.989-0.998), and undergoing Hybrid procedure relative to Norwood/right ventricle to pulmonary artery conduit (HR = 1.40, CI: 1.02-1.93). There was significant center variation in the number of readmissions and duration of readmissions. Unanticipated readmissions are common during the interstage period with notable center variation. However, these readmissions are short and are rarely in response to major adverse events.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 28417868     DOI: 10.1053/j.semtcvs.2016.08.011

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  4 in total

1.  Characterization of "ICU-30": A Binary Composite Outcome for Neonates With Critical Congenital Heart Disease.

Authors:  Monique M Gardner; Garrett Keim; Jill Hsia; Anh D Mai; J William Gaynor; Andrew C Glatz; Nadir Yehya
Journal:  J Am Heart Assoc       Date:  2022-06-14       Impact factor: 6.106

2.  Association of a Home Monitoring Program With Interstage and Stage 2 Outcomes.

Authors:  Monique M Gardner; Laura Mercer-Rosa; Jennifer Faerber; Michael P DiLorenzo; Katherine E Bates; Alyson Stagg; Shobha S Natarajan; Anita Szwast; Stephanie Fuller; Christopher E Mascio; Desiree Fleck; Deborah L Torowicz; Therese M Giglia; Jonathan J Rome; Chitra Ravishankar
Journal:  J Am Heart Assoc       Date:  2019-05-21       Impact factor: 5.501

3.  Initial Experience with Telemedicine for Interstage Monitoring in Infants with Palliated Congenital Heart Disease.

Authors:  Alyson Stagg; Therese M Giglia; Monique M Gardner; Bonnie F Offit; Kate M Fuller; Shobha S Natarajan; David A Hehir; Anita L Szwast; Jonathan J Rome; Chitra Ravishankar; Benjamin L Laskin; Tamar J Preminger
Journal:  Pediatr Cardiol       Date:  2022-09-01       Impact factor: 1.838

4.  Interstage Home Monitoring for Infants With Single Ventricle Heart Disease: Education and Management: A Scientific Statement From the American Heart Association.

Authors:  Nancy A Rudd; Nancy S Ghanayem; Garick D Hill; Linda M Lambert; Kathleen A Mussatto; Jo Ann Nieves; Sarah Robinson; Girish Shirali; Michelle M Steltzer; Karen Uzark; Nancy A Pike
Journal:  J Am Heart Assoc       Date:  2020-08-11       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.